GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (FRA:IL3) » Definitions » Net Issuance of Preferred Stock

Integra Lifesciences Holdings (FRA:IL3) Net Issuance of Preferred Stock : €0 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Integra Lifesciences Holdings Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Integra Lifesciences Holdings's net issuance of preferred for the three months ended in Mar. 2024 was €0 Mil. The number is 0, which means that Integra Lifesciences Holdings has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Integra Lifesciences Holdings's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was €0 Mil.


Integra Lifesciences Holdings Net Issuance of Preferred Stock Historical Data

The historical data trend for Integra Lifesciences Holdings's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Net Issuance of Preferred Stock Chart

Integra Lifesciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Integra Lifesciences Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Integra Lifesciences Holdings Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integra Lifesciences Holdings Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Integra Lifesciences Holdings (FRA:IL3) Business Description

Traded in Other Exchanges
Address
1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Integra Lifesciences Holdings (FRA:IL3) Headlines

No Headlines